142 related articles for article (PubMed ID: 8033751)
21. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds.
Vermeulen NP; Baldew GS; Los G; McVie JG; De Goeij JJ
Drug Metab Dispos; 1993; 21(1):30-6. PubMed ID: 8095223
[TBL] [Abstract][Full Text] [Related]
22. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
23. [Cisplatin nephrotoxicity: clinical observation and animal experiment].
Qiu XF; Li ZX
Zhonghua Fu Chan Ke Za Zhi; 1992 Jan; 27(1):35-7, 59. PubMed ID: 1505276
[TBL] [Abstract][Full Text] [Related]
24. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
25. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
Uehara T; Tsuchiya N; Masuda A; Torii M; Nakamura M; Yamate J; Maruyama T
J Appl Toxicol; 2008 Apr; 28(3):388-98. PubMed ID: 17685399
[TBL] [Abstract][Full Text] [Related]
26. Effect of oral administration of Arabic gum on cisplatin-induced nephrotoxicity in rats.
Al-Majed AA; Abd-Allah AR; Al-Rikabi AC; Al-Shabanah OA; Mostafa AM
J Biochem Mol Toxicol; 2003; 17(3):146-53. PubMed ID: 12815610
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats.
Atessahin A; Yilmaz S; Karahan I; Ceribasi AO; Karaoglu A
Toxicology; 2005 Sep; 212(2-3):116-23. PubMed ID: 15946783
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.
Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B
Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Gory-Delabaere G; Cupissol D; Brès J; Gau F; Constans B; Nouguier-Soulé J
J Soc Biol; 1999; 193(1):49-55. PubMed ID: 10851556
[TBL] [Abstract][Full Text] [Related]
34. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
36. [Clinical pharmacokinetics of cis-diamminedichloroplatinum (DDP)].
Zhang M
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):67-9. PubMed ID: 1396051
[TBL] [Abstract][Full Text] [Related]
37. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats.
Mohan IK; Khan M; Shobha JC; Naidu MU; Prayag A; Kuppusamy P; Kutala VK
Cancer Chemother Pharmacol; 2006 Dec; 58(6):802-8. PubMed ID: 16552571
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion.
Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL
Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945
[TBL] [Abstract][Full Text] [Related]
39. Control of nephrotoxicity by hydration-diuresis, and of emesis by alizapride, during cisplatin administration in patients with bladder cancer.
Neri B; Bartalucci S; Rizzo P; Nicita G; Ponchietti R
Riv Eur Sci Med Farmacol; 1988 Nov; 10(5):389-92. PubMed ID: 3079128
[No Abstract] [Full Text] [Related]
40. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
